The CBD Epilepsy Series Could Not Provide Seizure-Type-Specific Response Estimates
The adult epilepsy study reported overall seizure-frequency responses but did not calculate reliable response estimates for individual seizure types. Its aggregate result should not be assigned automatically to every seizure category.
The underlying clinical records were heterogeneous
The investigators collected seizure information from patient or caregiver diaries and medical records. They explain that mixed semiologies and variation in recorded counts prevented reliable seizure-type-specific quantification. Baseline and follow-up totals therefore supplied a broader clinical measure.
A responder threshold does not identify which events changed
A reduction of at least 50% in total frequency can arise from different changes across a patient’s seizure types. It does not show that each type fell by the same proportion, or that a specific disabling type responded. The paper does not support inventing a tonic-clonic, focal or absence-seizure response rate from its overall percentage.
The limitation affects individualized interpretation
The series included selected adults with severe epilepsy syndromes and changing concomitant medication. Its results describe observed clinical experience, not a randomized type-specific treatment effect. A useful account states how the events were counted and which detail was unavailable. The aggregate response can remain informative while the more specific efficacy question stays unresolved; lack of a type-specific analysis is not a demonstrated null result for any particular type.
Related analysis: the source’s broader findings and limitations.
